Monthly Archives: July 2013
Thursday, July 18, 2013
By Jerry McConnell
We’ve had some bad presidents over the nearly two and one half centuries of our existence, but never as bad and more troubled as we have seen and continue to see from the likes of Barack Hussein Obama. This plant, quite unexpectedly, came on to our scene with absolutely NO proven background, and no positive credentials of any national significance. His administration since taking over the role of President in a Usurper status, has been the most administratively faulty and scandal plagued, foolish and perilously reckless and profligately doling out our taxpayers’ money in a bankrupting manner outright to openly declared enemies whom he has befriended.
Among these recipients of his grandstanding and our sorrow are the Islamic terrorists, corrupt anti-American United Nations members, as well as to personal friends and family. All this and more while our national debt numbers keep skyrocketing into never before heard of brackets that would embarrass a collective group of ultra rich oil barons.
Sadly for the United States, he is having much fun doing it spending obscene amounts of taxpayer dollars and fueling higher national debt numbers and as reported, he curses revered honorable events such as Independence Day because he could have been playing golf instead. He is making a mockery of our government and thumbing his nose at the very people WHO PAY THE GREATEST BULK OF TAXES FOR OUR GOVERNMENT.
There is no question that he is accomplishing the assassination and demise or our once great nation (circa BO; Before Obama). He is on a mission of national destruction that was neither programmed nor spoken of prior to his ascendency to the power of the presidency, under false pretenses of legal citizenship, ever attempting to hand over our sovereignty to the corrupt and greedy United Nations through personally concocted treaties unwanted by the public.
There is also not much question that he and his personal staff of czars and cabinet members are all working tirelessly to find more and more ways to totally destroy our beloved Constitution, proclaimed all over the world as the best and longest lasting legal document of all similar essays of all the countries in the world. His most recent attack on our staff of support and bible of laws came ironically during this month of birth of our independence from tyranny just as he is now exhibiting.
In the Freedom Outpost on July 11, 2013, Dean Garrison authored “US Citizens Sign Petition For Obama To Repeal Bill of Rights”. Can you believe it, the fundamental underpinnings of the initial rights of our country’s constitution for the people, including freedom of speech and religion, freedom to bear arms, and actually all of the freedoms that we as American enjoy in our daily lives?
Garrison spoke of “a bunch of apathetic Obama-worshippers who probably don’t know what the Bill of Rights is. Make no mistake my friends. If Obama could have 300 million people in America with this mentality he would. This is exactly how really bad people gain power. If you gain control of enough “useful idiots” then you have a power base that is tough to overcome.”
The author cites this quote from one of, if not the most flagrant tyrants in the history of the world, Germany’s Adolph Hitler; this domineering, slick-talking murderer said, “How lucky for those in power, that people don’t think.”
How lucky indeed. To think that after all the egregious mistakes and scandalous events in just Obama’s first half year of his second term, let alone the many scary things from his first term in total, his lemmings, or those so densely imbued with his karma and charisma, and trickery and deceit as to be deaf, dumb and blind to keep his approval record in these, his worst days, still at or near the fifty percent mark. No wonder the man is going for broke and wants the high levels of the United Nations to enshrine him at the head of the entire world.
Then, as if the scandals in Obama’s Departments of the Executive Branch, IRS, NSA, and State, to mention just a few, Obama was not content to quit while his favorable numbers had only slipped a few slots below the 50 percent mark, he decided in his addelpated brain to once again thumb his nose at the taxpayers of the country who support the mining of coal.
in the words of Suzanne Hamner of Freedom Outpost and the Daily Caller, “Obama Will Use $8 Billion Of Taxpayer’s Money To Wage War On Coal, Leaving Thousands Unemployed” online July 10, 2013. In addition to adding MORE unnecessary and unneeded billions to our lofty and unparalleled national debt, his vendetta against 280 coal-fired generating plants could cost the jobs of thousands of the employees at those plants.
Hey, you Obama voters, how’s all that mountainous national debt and the loss of thousands more jobs sitting with you now?
Jerry McConnell is a longtime resident of planet earth with one half century on the seacoast of NH. He is a community activist but promises not to run for President and he feeds ACORN’s to the squirrels. He can be emailed at email@example.com with complaints or the editor at firstname.lastname@example.org with favorables.
Shell’s massive Olympus tension leg platform (TLP) set sail from Ingleside, Texas on 14th July, for a 425 mile trek to its final home on the Mars Field in the Gulf of Mexico.
For 10 days, tugboats will transport the over 120,000 ton platform to the location where work will begin to secure the platform in place. The Olympus TLP will be moored to the seafloor by tendons grouped at each of the structure’s corners and will float in approximately 3000 feet of water.
The Olympus TLP is Shell’s sixth and largest tension leg platform and will provide process infrastructure for two of Shell’s deep water discoveries, West Boreas and South Deimos. The project also includes pipelines that will be routed through West Delta 143C, the recently installed shallow water platform.
The Olympus TLP is expected to start production in 2014, producing at a rate of 100k boe.
• SECRET agreement between the Obama administration and the Muslim Brotherhood (not the Egyptian government) to give 40% of the Sinai and the annexation of that part of Egyptian territory in Gaza. The objective is to facilitate the conclusion of a comprehensive peace agreement between Israel and the Palestinians
• This agreement was signed by Khairat el Shater (number 2 of the Brotherhood) by Morsi and the Supreme Guide FM. (FM stands for Muslim Brotherhood)
• A sum of U.S. $ 8 billion was paid in exchange for FM.
• The document was seized by the army following the deposition of Morsi. This is the army that has leaked the news.
• An investigation is ongoing Morsi and El Shater. An arrest warrant was filed against the Guide to FM and other members of his office.
• FM signatories to the agreement are liable to the death penalty for treason.
• The Obama administration would try to reach an agreement with el Sissi (chairman of the Supreme Council of the Armed Forces): recognition of the legitimacy of the “coup” in exchange for his silence about the secret agreement. But el Sissi would be more interested in the conviction of FM and discredit their organization which is Egypt’s main source of danger.
• The Republican members of Congress are seriously looking into the case. If proven, the process of Obama impeachment could be triggered.
Source and Video: Here
Chris Jacobs July 12, 2013
One day after The Washington Post reported that federal taxpayer dollars could be used to promote Obamacare through porta-potties, the same outlet posted this e-mail from a Kentucky state official on how the Commonwealth plans to use federal funds to promote Obamacare:
I briefly scanned a schedule of upcoming mobile tour events and below few [sic] that are attended by a large number of young people: regional sporting events, such as the Lexington Legends and Louisville Bats games; the Goettafest and Riverfest in Newport and Covington; the Kentucky Bourbon Festival in Bardstown, Ky.; the Bourbon Chase; Oktoberfest in Newport; the Bourbon and Blues Festival in Owensboro; a couple of half marathons in various locations; the Iron Man competition, etc. We also expect that Navigators will be doing outreach on college campuses.
In other words, Kentucky plans a beer-and-bourbon tour to try to attract young people to enroll in Obamacare. (Maybe that’s what the porta-potties are for.)
The ironies abound in this announcement. Last year, the New York Post reported that New York City Mayor Michael Bloomberg proposed using community transformation grant funds from Obamacare to “reduc[e] alcohol retail outlet density and illegal alcohol.” So as Kentucky is using Obamacare funds to promote alcohol consumption, New York City wants to use Obamacare funds to discourage it. Apparently, the left hand doesn’t know what the far-left hand is doing.
Second, alcohol abuse costs taxpayers billions of dollars every year. A 2011 Centers for Disease Control study found that alcohol abuse cost federal, state, and local taxpayers a total of $94.2 billion each year. To the extent that these Obamacare promotional activities encourage alcohol abuse, they will inevitably impose new burdens on taxpayers—and raise overall health costs, contradicting the law’s stated purpose.
Just as important, these types of theatrical “marketing” activities represent a misuse of taxpayer dollars at a time of record debt and deficits. Congress should tell the Administration to stop handing out Obamacare grants like drunken sailors and refuse to spend a single dime funding Obamacare.
June 28, 2013
While Congress and federal health agencies have been constantly busy enacting new healthcare and drug legislation and implementing various regulations, one key issue has remained at the forefront—drug shortages. For example, the University of Utah Drug Information Service counted 300 “active” — or ongoing — drug shortages at the end of April, just about the same as it did at the end of December 2012 (299 shortages) and September 2012 (282 shortages), as reported by Medpage Today.
On the brighter side, the number of new shortages is well off its pace from years past, with 54 so far this year, Erin Fox, PharmD, director of the school’s Drug Information Service in Salt Lake City, said. There were 204 new shortages last year and 267 in 2011.
However, a national survey published in the April 1 issue of the American Journal of Health-System Pharmacy found that of almost 25 oncology pharmacists, 93% reported delays in chemotherapy administration or changes in treatment regimens, 85 percent saw higher costs and 10 percent experienced reimbursement challenges, reported FierceHealthCare. “Shortages of cancer drugs also led to additional labor expenses to address the problem, such as the extra hours hospital pharmacists spend trying to locate and purchase scarce medications or find alternatives, according to a research announcement from St. Jude Children’s Research Hospital.”
Moreover, the drug shortages resulted in potential medical errors for 16 percent of survey participants, while 6 percent attributed one or more actual medication errors to the shortages.
Over the past several months there has continued to be several issues regarding drug shortages—despite the legislative and regulatory fixes that Congress and the Food and Drug Administration (FDA) have put into place. Stakeholders from all areas have attempted to address continuing concerns about such shortages as well as their causes and ways to fix them.
For example, in late May of this year, U.S. Representative Elijah Cummings (D-MD) introduced the The Gray Market Drug Reform and Transparency Act of 2013 (PDF) (H.R. 1958(, who first introduced it in the House of Representatives last year. The 2012 legislation, however, did not pass out of the Energy and Commerce Committee’s Subcommittee on Health.
The legislation came after a report Cummings co-authored with Sens. John Rockefeller (D-WV) and Tom Harkin (D-IA), which we previously covered. The report found that “many hospitals and healthcare providers were unable to procure injectable cancer drugs from their usual and reputable sources. At the same time, those sources had reported being bombarded with unsolicited calls offering the hospitals and healthcare providers the same drugs, but with a catch: The drugs were subject to massive markups,” reported RAPS.
To address these concerns, the revived legislation (which is nearly identical according to RAPS), would among other things:
- prohibit wholesale distributors from purchasing prescription drugs from pharmacies
- establish a “National Wholesaler Database,” which would track information about wholesalers’ licenses, personal information, contact information and areas of operation
- establish fees for wholesale distributors
- require companies selling drugs experiencing a shortage to provide purchasing organizations with the original purchase price of the drugs
- encourage state regulators to share wholesaler information, including records of disciplinary action, with the proposed National Wholesaler Database
Drug Shortages and Lyme Disease
Next, Senator Susan Collins (R-ME), along with Senator Amy Klobuchar (D-MN) recently sent a letter urging FDA Commissioner Dr. Margaret Hamburg to take steps to alleviate the shortage of doxycycline, an oral antibiotic used to treat Lyme disease and other infectious diseases.” In a press release regarding the letter, reported by Bangor Daily News, Collins wrote, “The antibiotic doxycycline is critically important for treating these patients, and it’s imperative that the FDA do all it can to help alleviate this shortage.”
Both Maine and Minnesota have high incidences of tick-borne illnesses. A record-high 1,100 Maine residents were diagnosed last year with Lyme disease, and public health officials have warned that the risk for Lyme has increased now that ticks have emerged for the season. “According to our state epidemiologist, the number of Maine residents diagnosed with Lyme disease continues to increase each year,” Collins said in a press release about the letter. “The antibiotic doxycycline is critically important for treating these patients, and it’s imperative that the FDA do all it can to help alleviate this shortage.”
The FDA first reported a shortage of doxycycline on Jan. 18. Maine hasn’t yet experienced any shortages, according to the Maine Center for Disease Control and Prevention, which is monitoring supplies.
Drug Shortages and Tuberculosis
Healthday recently reported that many health departments have altered treatment practices for tuberculosis (TB) because of drug shortages. The specific drug, isoniazid (INH), was first used in 1951 and is one of four drugs considered to be the core of any first-line treatment for tuberculosis (TB). Patients must take the drugs for six to nine months, according to the U.S. Centers for Disease Control and Prevention.
However, a national survey of local health departments around the country in January found that many health departments and clinics were having trouble getting INH. According to the report, published in the May 24 issue of the CDC publication, Morbidity and Mortality Weekly Report, the shortage first became severe in November 2012 and was attributed to manufacturing and supply problems.
The January survey, conducted by the National Tuberculosis Controllers Association online, was sent to 68 jurisdictions in all 50 states, including health departments in 10 large U.S. cities.
The survey found that 79 percent of the TB programs that responded said they were having difficulty obtaining INH, 41 percent said they would run out of the drug within a month and 15 percent no longer had any of the drug left.
To deal with the shortage, 69 percent of the TB programs said they switched suppliers, 72 percent prioritized high-risk patients, 68 percent delayed treatment and 88 percent tried alternative treatments. Forty-four percent said they switched to more expensive TB drug regimens.
The CDC researchers said that while the shortage of INH is easing, many health departments still can’t get supplies of the drug and have changed their treatment practices to deal with the shortage. The CDC is working with local, state and international officials, along with suppliers of INH, to alleviate the shortage.
FDA Importing Injectable Nutrition Drugs
Next, in late May of this year, FDA announced that it would begin importing injectable nutrition drugs to address shortages of drugs needed to treat premature infants, patients unable to eat or drink by mouth. FDA announced that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients in late May, early June of this year.
TPN is an intravenous food solution containing several drugs that have been in short supply, including trace elements, potassium phosphate, and sodium phosphate. Hospitals nationwide rely on TPN, which is primarily used to treat premature infants who are unable to eat or drink by mouth or who are experiencing other deficiencies. Cancer patients and those who have had gastrointestinal surgeries who are also unable to eat or drink by mouth have been affected by these shortages.
“While we have made progress on the critical issue of drug shortages, we remain extremely concerned about all current and potential drug shortages, and we are vigilant in our efforts so patients have access to the medicines they need, when they need them,” said FDA Commissioner Margaret A. Hamburg, M.D. “The FDA is doing all it can, using every tool we have to resolve and prevent drug shortages.”
The FDA is exercising regulatory discretion for Fresenius Kabi USA, LLC, based in Lake Zurich, Ill., to import trace elements and phosphate injection from its Norway plant so the drugs can reach Americans in need.
The shortages are largely the result of a decision by American Regent/Luitpold, a large manufacturer of TPN products, to temporarily shut down at the end of 2012. The FDA worked with American Regent in an effort to avoid a shutdown. The company, however, ultimately decided that it had to cease operations temporarily in order to address quality issues that included particulate matter in its injectable products. The FDA continues to work with the company to prioritize the most critical drugs in shortage as it restarts production, and on the quality issues, to protect patient health.
Previously, 14 bipartisan senators, led by Sen. Al Franken (D-Minn.), wrote the FDA last week urging action to mitigate the drugs. “It is essential that we do all we can to prevent shortages in products that compose total parenteral nutrition so that children’s hospitals can again focus on providing the best care to their patients,” the senators wrote, as reported by Medpage Today.
Upon learning of American Regent’s decision to temporarily shut down, the FDA looked for ways to increase supply and ultimately sought foreign companies willing and able to help the United States resolve these shortages. When the FDA looks for a foreign source to bolster supply in the U.S., the agency evaluates the foreign drug to ensure that it is of adequate quality and does not pose undue risks for U.S. patients.
“TPN component shortages have been a high priority for the agency. Since the onset of these shortages, the FDA has been very concerned about the dwindling supply of injectable nutrition products and the effect this is having on children’s hospitals treating vulnerable patients,” said Valerie Jensen, R.Ph., associate director of the drug shortages program in the FDA’s Center for Drug Evaluation and Research. “We believe the import of these injectable nutrition drugs is going to meet current supply needs over the coming weeks.”
The FDA’s exercise of enforcement discretion for these TPN components is temporary, and applied to address this critical shortage. While the FDA cannot force a manufacturer to make a product, the agency will continue to provide expedited regulatory review and advice to manufacturers of TPN components and other drugs most in need.
Other manufacturers of TPN components, including Hospira, Inc. of Lake Forest, Ill., are also working to increase supplies of these critical drugs.
Since 2010, the FDA has used its regulatory discretion for the importation of 14 drugs. With the addition of these injectable nutrition drugs, the total will be at 17
Drug Shortages and Anesthesia
On somewhat of a positive note, a survey in early May of this year released by the American Association of Nurse Anesthetists showed that improved communication between drug manufacturers, pharmacists, anesthesia providers, and FDA would help mitigate anesthesia drug shortages that continue to disrupt patient access to healthcare by forcing the cancellation of surgical and other procedures. Approximately 2,500 Certified Registered Nurse Anesthetists (CRNAs) responded to the survey conducted by the American Association of Nurse Anesthetists (AANA).
“Cancellations imperil our healthcare system by increasing costs, inconveniencing patients, and potentially placing both anesthesia professionals and their patients at risk for adverse health outcomes,” said Janice Izlar, CRNA, DNAP, president of the 45,000 member AANA. “However, the results of the AANA’s recent drug shortage survey suggest that cancellations can be reduced through better communication among those who manufacture, regulate, and administer anesthesia drugs.”
The February 2013 survey showed that little progress has been made to alleviate anesthesia-related drug shortages. Ninety percent of CRNAs reported that their facilities are currently experiencing shortages, as compared with 95 percent in 2011. Nearly six percent of CRNAs responding to the survey indicated that the drug shortages have caused cases to be cancelled, virtually unchanged from a year and a half ago.
While the shortages continue, healthcare facilities are taking action to minimize schedule disruptions as much as possible by modifying anesthesia techniques, group purchasing drugs, using in-house pharmacies to compound syringes, and conserving drugs that are in short supply when other anesthesia options are available. However, according to survey respondents the most effective measure has been timely communication between pharmacy and anesthesia staff about drug shortages.
“Equally important to effective communication within facilities,” said Izlar, “is consistent, timely communication about shortages from the FDA and drug companies to the healthcare professionals in the facilities.” Interestingly, only 27.3% of respondents said they found FDA’s drug shortage website “valuable”, relying more on formal facility planning (66.3%) and facility/departmental meetings (41.4%). CRNAs responding to the survey identified the following drug shortage information as most valuable to their practice:
- advance notice of a drug shortage (77 percent);
- anticipated duration of a shortage (76 percent);
- alternative drug choices and techniques (64 percent);
- medication inventory availability (53 percent); and
- source of the shortage (47 percent).
Other findings show that respondents had a number of restrictions or changes to their practice because of drug shortages. For example:
- ~75% had conservation measures placed on drugs
- ~73% had large, single-does vials as the only size of drug available
- 68.2% had to modify the anesthesia technique or management of hemodynamic changes
- 57.5% had to use a pharmacy to prepare smaller, single-dose syringes (which is troubling given all the recent compounding pharmacy scares)
- 45.6% said they themselves prepared smaller, single-dose syringes
- 21.7% had delayed emergency or recovery.
Despite government intervention, drug shortages remain. One solution may be eliminating the price controls for generic injectable drugs which would allow for additional manufacturers incentives to enter the market and expand the supply.
This week the SubseaIQ team added 5 new projects and updated 23 projects. You can see all the updates made over any time period via the Project Update History search. The latest offshore field develoment news and activities are listed below for your convenience.
Asia – SouthEast
Jul 12, 2013 – Premiere Oil announced that on June 21 a planned 4-week shutdown of the Anoa field gas processing facility commenced to allow the completion of the Phase 4 compression project. The project was implemented to add additional gas processing capacity to handle the decline of oil production and the increase of associated gas production. First gas is expected near the end of July with final commissioning to be complete by September. Phase 4 will allow the commercialization of roughly 200 Bcf of undeveloped proven reserves. The Anoa field is located off Indonesia in Natuna Sea Block A. Premier (28.667%) operates the field on behalf of its partners KUFPEC (33.33%), Hess (23%) and Petronas (15%).
Project Details: Anoa
Jul 12, 2013 – KrisEnergy, operator of the Kutai PSC offshore Indonesia, announced the completion of drilling operations at the Tayum-1 exploration well. Shelf Drilling’s Randolph Yost (300′ ILC) drilled the well directionally to a measured depth of 11,095 feet (8,410 feet total vertical depth). Almost 50 feet of net gas pay was encountered over multiple sandstone intervals. The well has been plugged and abandoned as a gas discovery.
Project Details: Tayum
Jul 11, 2013 – Nido Petorleum secured a 12-month extension from the Philippines Department of Energy relating to Sub-Phase 6 for Service Contract (SC) 54A. Sub-Phase 6 now has an effective end date of Aug 4, 2014 and Sub-Phase 7 will commence Aug 5, 2014 and last for 12 months. The extension allows Nido and its partners additional time to complete engineering and development studies prior to making the decision on whether or not to enter Sub-Phase 7. Lawaan is the leading drillable prospect in SC54A with oil-in-place estimates of 34.7 million barrels.
Project Details: Lawaan
Africa – West
Jul 11, 2013 – Ophir Energy’s Starfish-1 well has been drilled to 14,370-feet total depth (TD) by the Stena DrillMax (UDW drillship) in the Accra PSC offshore Ghana. A wireline logging program was carried out in the well that confirmed over 750 feet of gross water-bearing sandstone in the primary target. The secondary target was determined to be comprised of poorly developed sands that were also water-bearing. Evaluation of the logging data will continue in an effort to help the PSC partners decide by the Sept. 23-deadline on whether or not to proceed with the Phase 2 work program.
Project Details: Starfish
Jul 11, 2013 – The partners in Namibian license PEL0010 selected the new-build Rowan Renaissance (UDW drillship) to drill the Welwitschia-1 exploration well. Rig delivery is expected to take place in December 2013, at which point the drillship will sail directly to Namibia to spud the well in mid-February 2014. Detailed well planning is underway and a site has been selected that will allow the well to test the primary and secondary targets in Maastrichtian and Aptian-Albian reservoirs. Procurement of long-lead items is underway with deliveries to begin by the end of the year. License partners include Repsol (44%) as operator, Tower Resources (30%) and Arcadia (26%).
Project Details: Welwitschia
Europe – North Sea
Jul 12, 2013 – Bridge Energy, a partner in UK license P1763, announced the Blackford Dolphin (DW semisub) has been contracted by operator-MPX North Sea to test the Aragon prospect with an estimated spud date in 1Q 2014. Aragon is located near the Beryl field and the well will be target sands in the Upper Jurassic Heather formation. Drilling the exploration well will fulfill a work commitment that needs to be completed before 1Q 2015.
Project Details: Aragon
Jul 12, 2013 – Premier Oil and KUFPEC Norway AS have entered into an agreement to acquire BG Group’s entire 40% interest in license PL407 on the Norwegian continental shelf. If approved by regulatory authorities, the revised license ownership will consist of Premier (50%) as operator, KUFPEC (30%) and Tullow (20%). PL407 contains the Bream discovery which has been estimated to contain around 50 MMboe. Development of the field is expected to be sanctioned at some point in 2014.
Project Details: Bream
Jul 12, 2013 – Lundin Petroleum announced the successful completion of its latest Johan Sverdrup appraisal well. Well 16/3-6 was drilled by the Bredford Dolphin (mid-water semisub) to a depth of 6,643. A 37-foot oil column was discovered in good quality Upper Jurassic sandstone. The rig will now mobilize to license PL544 to drill well 16/4-7 on Lundin’s Biotitt prospect.
Project Details: Johan Sverdrup
Jul 12, 2013 – Cairn Energy’s 38% farm-in as operator of Frontier Exploration Licenses (FEL 2/04) and 4/08 has been approved by Ireland’s Minister of State at the Department of Communications, Energy and Natural Resources (DCENR). License FEL 2/04 contains the Burren and Spanish Point discoveries and FEL 4/08 holds the Cama oil prospect. Cairn has contracted the Blackford Dolphin (DW semisub) to drill an appraisal well at Spanish Point in 2Q 2014. In addition to the two FELs, Cairn also secured operatorship of a licensing option in the Porcupine Basin covering 1,062 square miles.
Project Details: Spanish Point
Jul 11, 2013 – The Norwegian Petroleum Directorate (NPD) granted Statoil a permit to drill an exploration well at its Iskrystall prospect in license PL608. Well 7219/8-2 will be drilled by the West Hercules (UDW semisub) in 1,128 feet of water. The well will test a similar early-middle Jurassic play that was proven by the Skrugard and Havis discoveries but is thought to lie at a much greater depth at Iskrystall.
Project Details: Iskrystall
Jul 11, 2013 – Lundin Petroleum announced the spud of well 16/2-18S in Norwegian license PL265. The well is being drilled by the Ocean Vanguard (mid-water semisub) to test the presence of quality Jurassic reservoir and the quality of fractured and weathered basement rock. Additionally, the well will serve to delineate the northeast extension of the Johan Sverdrup discovery. The rig is expected to be on location for 40 days while drilling to the proposed total depth of 6,463 feet.
Project Details: Johan Sverdrup
Jul 11, 2013 – A wireline logging program being carried out in Apache’s Bianchi-1 well off Western Australia was interrupted to conduct unspecified repairs to the Ocean America (DW semisub). Enough data was acquired prior to the shut-down, confirming a gas discovery in the upper sands of an interval that LWD data indicated to be gas-bearing. The Bianchi joint venture has agreed to drill an additional 100 feet to a total depth (TD) of 17,789 feet. Upon reaching TD, the wireline program will recommence to complete the evaluation of the well.
Project Details: Bianchi
Jul 11, 2013 – IPB Petroleum and CalEnergy were granted a 12-month suspension and extension to years 2 and 3 regarding the work program for permit WA-424-P off Western Australia. A tight rig market prompted the joint venture partners to seek the extension in order to have more time to source a suitable rig to drill an exploration well on the Pryderi prospect. The extra time also allows for the submission of needed revisions to the Pryderi Environmental Plan and Oil Spill Contingency Plan. Submission of the revisions is expected to take place mid-July 2013. Assuming the revisions are accepted and all regulatory approvals are granted, IPB expects to be ready to spud Pyderi-1 in 4Q 2013.
Project Details: Pryderi
Edison Chouest Offshore said today it will build more than 40 new vessels to meet growing demand for offshore oil and gas support in the Gulf of Mexico, the Arctic and Brazil.
The new vessels continue an aggressive build campaign the Galliano-based company launched in 2011. The privately held company, which has vessels under construction at shipyards through the U.S. and in Brazil and Poland, did not disclose the cost of the newest round of builds.
Most of the construction work will be spread among Chouest’s four U.S.-affiliate shipyards — North American Shipbuilding in Larose, LaShip in Houma, Gulf Ship in Gulfport, Miss., and Tampa Ship in Tampa, Fla. — as well as its Brazilian shipyard, Navship.
The largest portion of the new build program will be the construction of 17 diesel-electric platform supply vessels. Chouest intends to market the new vessels, which feature a new hull form designed to carry more weight while lowering hydrodynamic resistance, as a more fuel-efficient option to oil and gas operators in the Gulf of Mexico.
Chouest’s plans also include two new ice class vessels designed for service work in the Arctic and four new subsea construction vessels slated for service in the Gulf of Mexico. The company’s fleet of icebreaking vessels, which will total six when the new builds are delivered, has supported Royal Dutch Shell’s drilling activity in Alaska.
Chouest also provided an update about its affiliated port facilities at Port Fourchon. The C-Port 3 facility currently under construction will open in March and feature six covered slips to transfer cargo and provide support for deepwater support vessels. Design has begun on an additional section, C-Port 4, which could have as many as nine covered slips.
The company is also planning to expand its C-Terminal worksite at Fourchon to include outside storage areas, warehouses, cement and barite plants, and fuel, water, mud and drilling fluid sales stations. Chouest purchased the facility earlier this year.
Chouest, founded as Edison Chouest Boat Rental in 1960, operates a fleet of nearly 250 offshore service and support vessels worldwide.